One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...

Ignore the noise in GLP-1 stocks. Find the best value instead.

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

Ireland is swimming in cash. US tech giants such as Apple, Microsoft, Google and Meta, and pharma groups including Pfizer and ...

Pharma firms are among many pausing diversity programmes and promising domestic investment ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Indiana University Health is building a new hospital on a 44-acre campus in Indianapolis. The facility will consolidate the ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

House Bill 1879 passed unanimously March 4 on a 95-0 vote, according to the chamber's website. State senators will now ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...